Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zr-Panitumumab for Assessment of Suspected Metastatic Lesions in HNSCC
NCT05423197Phase 2Withdrawn
- Sponsor
- Andrei Iagaru
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zirconium Zr 89 panitumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Andrei Iagaru. Planned start Jun 2026; status: withdrawn.
02
Drugs
zirconium Zr 89 panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05423197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05423197.